Clinical Trial

Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer

Study acronym: Tox-DXd
Recruiting
View on ClinicalTrials.gov →
Summary
the anti-Human Epidermal Growth Factor Receptor 2 (HER2) Trastuzumab-Deruxtecan (T-DXd) has shown impressive clinical activity in pretreated patients with metastatic breast cancer (MBC) but is also associated with a non-negligible rate of adverse events that may lead to treatment discontinuation and/or the onset of pneumonitis/interstitial lung disease (ILD) The aim of the study is to identify and describe potentially predictive markers related to the onset of relevant T-DXd-related toxicities
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-25; most recent amendment 2026-01-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-02
Trial Details
NCT Number NCT07049133
Lead Sponsor European Institute of Oncology
Conditions Metastatic Breast Cancer
Enrollment 84 participants
Start Date 2025-07-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-06